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Eberhard Grube, MD, Georg Nickenig, MD, Nikos Werner, MD
Bonn, Germany
Objectives The aim of this study was to provide a simple, reproducible, and point-of-care assessment of peri-prosthetic aor-
tic regurgitation (periAR) during transcatheter aortic valve implantation (TAVI) and to decipher the impact of this
peri-procedural parameter on outcome.
Background Because periAR after TAVI might be associated with adverse outcome, precise quantification of periAR is of par-
amount importance but remains technically challenging.
Methods The severity of periAR was prospectively evaluated in 146 patients treated with the Medtronic CoreValve (Minne-
apolis, Minnesota) prosthesis by echocardiography, angiography, and measurement of the aortic regurgitation
(AR) index, which is calculated as ratio of the gradient between diastolic blood pressure (DBP) and left ventricu-
lar end-diastolic pressure (LVEDP) to systolic blood pressure (SBP): [(DBP  LVEDP)/SBP]  100.
Results After TAVI, 53 patients (36.3%) showed no signs of periAR and 71 patients (48.6%) showed only mild periAR,
whereas 18 patients (12.3%) and 4 patients (2.7%) suffered from moderate and severe periAR, respectively. The
AR index decreased stepwise from 31.7 10.4 in patients without periAR, to 28.0 8.5 with mild periAR, 19.6 7.6
with moderate periAR, and 7.6  2.6 with severe periAR (p  0.001), respectively. Patients with AR index 25
had a significantly increased 1-year mortality risk compared with patients with AR index 25 (46.0% vs. 16.7%;
p  0.001). The AR index provided additional prognostic information beyond the echocardiographically assessed
severity of periAR and independently predicted 1-year mortality (hazard ratio: 2.9, 95% confidence interval: 1.3
to 6.4; p  0.009).
Conclusions The assessment of the AR index allows a precise judgment of periAR, independently predicts 1-year mortality
after TAVI, and provides additional prognostic information that is complementary to the echocardiographically
assessed severity of periAR. (J Am Coll Cardiol 2012;59:1134–41) © 2012 by the American College of Cardiol-
ogy Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.048Transcatheter aortic valve implantation (TAVI) has evolved
as an alternative to surgical aortic valve replacement in
patients with symptomatic severe aortic stenosis who are
considered to be at very high or prohibitive operative risk
(1). Although the PARTNER (Placement of AoRTic
TraNscathetER Valve) trial recently demonstrated that
From the Medizinische Klinik und Poliklinik II, Universitätsklinikum Bonn, Rhei-
nische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany. Dr. Grube is a
proctor for CoreValve/Medtronic. All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose.Manuscript received September 11, 2011; revised manuscript received November
26, 2011, accepted November 29, 2011.TAVI is associated with similar mortality at 30 days and 1
year in surgical high-risk patients compared with surgical
aortic valve replacement, a number of TAVI-associated
drawbacks have been identified, including a higher inci-
dence of peri-prosthetic aortic regurgitation (periAR).
Recently published studies report an incidence of mod-
erate/severe periAR after TAVI of approximately 15% to
20% (1–6).
Precise echocardiographic or angiographic quantification
of periAR in TAVI patients remains challenging, especially
during implantation, despite the recently published Valve
Academic Research Consortium (VARC) criteria (7,8).
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March 27, 2012:1134–41 Aortic Regurgitation Index Predicts Outcome After TAVIHowever, the importance of accurately defining the severity
of periAR immediately after valve implantation (within the
catheterization laboratory) is paramount, because increasing
evidence suggests that periAR has a significant impact on
short- and long-term outcome after TAVI (2,6). Thus, an
objective parameter to assess directly and precisely the
severity of periAR in TAVI patients during the procedure is
essential to take effective countermeasures such as post-dilation,
snaring, or valve-in-valve implantation to decrease periAR.
The aim of our study was to provide a simple, reproduc-
ible, and point-of-care assessment of periAR during TAVI
and to decipher the impact of the aortic regurgitation (AR)
index, defined as the ratio of the gradient between diastolic
blood pressure (DBP) in the aorta and left ventricular
end-diastolic pressure (LVEDP) to systolic blood pressure
(SBP), on survival after TAVI.
Methods
Patient population. Patients (N  146) underwent TAVI
with use of the third-generation CoreValve prosthesis
(Medtronic, Minneapolis, Minnesota) and were included
into this prospective study after written informed consent.
Figure 1 Calculation of the AR Index
Simultaneous determination of left ventricular end-diastolic pressure (LVEDP)
(blue line) and diastolic blood pressure (DBP) in the aorta (red line) in a
patient without peri-prosthetic aortic regurgitation (periAR) (A) and in a patient
with moderate periAR (B) for the calculation of the aortic regurgitation (AR)
index: ([DBP  LVEDP]/SBP)  100. (A) AR index  ([65  10]/160) 
100  34.4. (B) AR index  ([40  20]/130)  100  15.4.oBefore TAVI, annulus dimension
was evaluated with 3-dimensional
transesophageal echocardiography
(TEE), angiography of the aortic
root, and multi-slice computed to-
mography. The TAVI was per-
formed with biplane fluoroscopy
under local anesthesia in combina-
tion with a sedative/analgesic treat-
ment. Intraprocedural TEEwas not
routinely performed, and the proce-
dure was predominantly guided by
angiographic control.
The primary endpoint of this
study was all-cause mortality at 1
year. Clinical outcomes and the
degree of periAR were defined
according to VARC criteria (7).
Information about the cause of
death was obtained from the treating hospital, referring
cardiologist, or general practitioner. The study was ap-
proved by the local ethics committee of the University of
Bonn.
Echocardiographic assessment of periAR. The occur-
rence and degree of periAR was assessed by angiography
immediately after TAVI and by transthoracic echocardiog-
raphy or TEE until Day 3 after TAVI according to the
recently published VARC criteria (7). The evaluation of
periAR was performed by a blinded echocardiographer who
did not attend the procedure.
Hemodynamic assessment of periAR. In all patients, the
pressure in the left ventricle and in the ascending aorta was
determined simultaneously after the procedure. The gradi-
ent between DBP in the aorta and LVEDP was calculated
over several cardiac cycles to evaluate the severity of periAR
(Fig. 1). To adjust the gradient for the respective SBP of the
patient, we calculated the dimensionless AR index accord-
ing to the following formula: [(DBP  LVEDP)/SBP] 
100. For our analysis, we used the final calculation of the
AR index just before the end of the TAVI procedure
(mostly within 10 to 15 min after valve deployment).
Statistical analysis. Data are presented as mean  SD if
ormally distributed or as median and interquartile range if
ot normally distributed. Continuous variables were
ested for normal distribution with the use of the
olmogorov–Smirnov test. Categorical variables are given
s frequencies and percentages. For continuous variables, a
tudent t test was performed for comparison between 2
roups. When comparing more than 2 groups, analysis of
ariance or the Kruskal–Wallis test was used. For categorical
ariables, the chi-square or Fisher exact test were used for
urther analysis.
The cutoff value of the AR index for the prediction of
ll-cause mortality at 1 year was determined in receiver-
perating characteristic curve analysis as maximum sum
Abbreviations
and Acronyms
AR  aortic regurgitation
CI  confidence interval
DBP  diastolic blood
pressure
HR  hazard ratio
LVEDP  left ventricular
end-diastolic pressure
periAR  peri-prosthetic
aortic regurgitation
SBP  systolic blood
pressure
TAVI  transcatheter aortic
valve implantation
TEE  transesophageal
echocardiographyf sensitivity and specificity to minimize both the number
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Aortic Regurgitation Index Predicts Outcome After TAVI March 27, 2012:1134–41of false positive and false negative findings. Survival
according to the occurrence of periAR and the AR index
cutoff value was determined with use of the Kaplan-
Meier method. We performed a multivariate Cox regres-
sion analysis to examine the association of the AR index
and the severity of periAR with 1-year mortality. Statis-
tical significance was assumed when the null hypothesis
could be rejected at p  0.05. Statistical analyses were
onducted with PASW Statistics (version 18.0.3, IBM
orporation, Somer, New York) and MedCalc (version
1.6.1.0, MedCalc Software, Mariakerke, Belgium). The
nvestigators initiated the study, had full access to the
ata, and wrote the manuscript. All authors vouch for
he data and the analysis.
Baseline Characteristics According to the SeveTable 1 Baseline Characteristics According
All Patients
(N  146)
Age (yrs) 80.5 6.6
Male 70 (47.9)
Logistic EuroSCORE (%) 30.2 18.0
STS score: mortality (%) 9.8 7.3
Body mass index (kg/m2) 24.7 (22.1/27.9)
Height (cm) 167.2 8.9
Weight (kg) 70.0 (63.0/80.0)
Coronary artery disease 89 (61.0)
Peripheral artery disease 55 (37.7)
Previous MI 43 (29.7)
Previous PCI 58 (39.7)
Previous CABG 18 (12.3)
Previous stroke 37 (25.3)
Chronic renal failure 82 (56.2)
COPD 40 (27.4)
Pulmonary hypertension 54 (37.0)
LVEF (%) 44.5 14.5
LVEF 30% 35 (24.0)
Aortic valve area (cm2) 0.67 0.15
Mean aortic gradient (mm Hg) 38.0 (29.0/51.0)
Pre-procedural AR
None 68 (46.6)
Mild 64 (43.8)
Moderate 13 (8.9)
Severe 1 (0.7)
Aortic annulus diameter (mm) 23.5 2.1
Aortic annulus 26 mm 21 (14.4)
Balloon valvuloplasty size (mm) 22.0 (20.0/25.0)
Implantation depth NCC (mm) 9.9 5.9
Implantation depth LCC (mm) 10.6 4.0
CoreValve prosthesis size
26 mm 64 (43.8)
29 mm 82 (56.2)
Access site
Transfemoral 134 (91.8)
Trans-subclavian 12 (8.2)
Values are mean  SD n (%).
AKI  acute kidney injury; AR  aortic regurgitation; CABG  coro
LVEF  left ventricular ejection fraction; EuroSCORE  European Syst
 myocardial infarction; NCC  non-coronary cusp; NT-proBNP  N-termin
Association; PCI  percutaneous coronary intervention; periAR  peri-prosthesults
aseline characteristics. The TAVI was performed in 146
atients at high risk for open heart surgery (mean Society of
horacic Surgeons mortality score: 9.8  7.3%; mean
ogistic European System for Cardiac Operative Risk Eval-
ation score: 30.2  18.0%). Echocardiographic assessment
f the periAR until Day 3 after TAVI demonstrated that 53
atients (36.3%) had no signs of periAR and 71 patients
48.6%) had only mild periAR, whereas 18 patients (12.3%)
nd 4 patients (2.7%) suffered from moderate and severe
eriAR, respectively. The echocardiographic periAR grad-
ng strongly correlated with the post-procedural angiogram
r  0.88; p  0.001) (Online Fig. 1). To meet the recently
f PeriARe Severity of PeriAR
Mild PeriAR
 124)
Moderate/Severe PeriAR
(n  22) p Value
.6 6.7 79.6 6.0 0.52
(42.7) 17 (77.3) 0.003
.0 18.0 31.4 18.1 0.75
.9 7.2 9.0 6.6 0.61
(22.3/28.0) 23.3 (21.0/27.0) 0.20
.0 8.1 173.8 10.1 0.001
(63.0/80.0) 70.0 (60.0/89.5) 0.88
(58.1) 17 (77.3) 0.09
(35.5) 11 (50.0) 0.20
(27.4) 9 (42.9) 0.15
(37.9) 11 (50.0) 0.29
(11.3) 4 (18.2) 0.37
(25.0) 6 (27.3) 0.82
(54.0) 15 (68.2) 0.22
(26.6) 7 (31.8) 0.61
(35.5) 10 (45.5) 0.37
.5 14.0 39.1 16.3 0.05
(21.8) 8 (36.4) 0.14
8 0.16 0.64 0.14 0.28
(29.8/47.3) 44.5 (24.8/58.3) 0.44
0.65
(48.4) 8 (36.4)
(42.7) 11 (50.0)
(8.1) 3 (13.6)
(0.8) 0 (0)
.2 1.9 25.1 2.4 0.001
(8.9) 10 (45.5) 0.001
(20.0/25.0) 25.0 (22.0/25.0) 0.001
.7 6.3 10.7 3.2 0.50
.2 4.1 12.3 3.2 0.029
0.70
(45.2) 8 (36.4)
(54.8) 14 (63.6)
0.13
(90.3) 22 (100.0)
(9.7) 0 (0)
ery bypass grafting; COPD  chronic obstructive pulmonary disease;
ardiac Operative Risk Evaluation score; LCC  left-coronary cusp; MIrity oto th
None/
(n
80
53
30
9
24.8
166
70.0
72
44
34
47
14
31
67
33
44
45
27
0.6
38.0
60
53
10
1
23
11
22.0
9
10
56
68
112
12
nary art
em for Cal pro-hormone brain natriuretic peptide; NYHA  New York Heart
etic aortic regurgitation; STS  Society of Thoracic Surgeons.
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March 27, 2012:1134–41 Aortic Regurgitation Index Predicts Outcome After TAVIpublished VARC criteria for the assessment of the severity
of periAR (7), the echocardiographic grading was used for
further analysis.
For the comparison of baseline characteristics, patients
were divided into 2 groups according to the occurrence of
echocardiographically confirmed periAR (none/mild vs.
moderate/severe) after TAVI. The latter was considered
clinically relevant. Patients with moderate/severe periAR
were more often male (77.3% vs. 42.7%; p  0.003) and
aller (173.8 10.1 cm vs. 166.0 8.1 cm; p 0.001) than
patients with none/mild periAR (Table 1). The mean aortic
annulus diameter was significantly larger (25.1  2.4 mm
vs. 23.2  1.9 mm; p  0.001) and the cover index was
ignificantly lower (10.1  6.1% vs. 16.0  4.6%; p 
0.001) in patients suffering from moderate/severe periAR,
compared with patients with none/mild periAR (Table 2).
Hemodynamic assessment of periAR. Simultaneous mea-
surement of the left ventricular and aortic pressure showed
a stepwise decrease of the gradient between LVEDP and
the DBP in the aorta with increasing degree of periAR (p
0.001) immediately after valve implantation (Table 2). In
patients with none/mild periAR, the LVEDP decreased
from 16.6  5.0 mm Hg before to 13.6  6.8 mm Hg
(p  0.001) after the procedure, whereas the LVEDP
ncreased during the TAVI procedure in patients with
ost-interventional moderate/severe periAR from 14.9 
.3 mm Hg to 18.3  6.2 mm Hg (p  0.001).
The AR index decreased in parallel with increasing
everity of periAR, from 31.7  10.4 in patients without
eriAR to 28.0  8.5 in patients with mild periAR, 19.6 
.6 in patients with moderate periAR, and 7.6  2.6 in
atients with severe periAR (p  0.001) (Fig. 2).
linical outcomes after TAVI. Of 146 patients, 10 (6.8%)
ied within the first 30 days after TAVI, and 39 (26.7%)
ied during follow-up of up to 1 year. The echocardio-
raphically assessed severity of periAR was significantly
ssociated with 30-day and 1-year mortality after TAVI
p  0.001 and p  0.001, respectively) (Table 3). In
atients with none/mild periAR, a 1-year mortality of
0.2% (25 of 124) was observed, compared with 63.6% (14
Hemodynamic Variables, AR Index, and Laboratory Parameters at 4Table 2 Hemodynamic Variables, AR Index, and Laboratory Par
All Patients
(N 146)
No PeriAR
(n  53)
LVEDP (mm Hg) 12.6 8.1 11.4 7.5
Aortic diastolic
pressure (mm Hg)
46.3 11.9 50.4 13.2
End-diastolic
gradient (mm Hg)
33.8 12.3 39.2 11.1
AR index 27.6 10.3 31.7 10.4
Cover index (%)* 15.1 5.2 16.0 4.5
NT-proBNP (pg/ml) 1,568.5 (601.5/5,475.5) 1,649.5 (765.3/5,814.8) 1,063.
Troponin I (ng/ml) 0.69 (0.30/1.73) 0.65 (0.28/1.48) 0.5Values are mean  SD or % (n/N). *According to the definition of Détaint et al. (4).
LVEDP  left ventricular end-diastolic pressure; NT-proBNP  N-terminal pro-hormone brain natriureticf 22) in patients with moderate/severe periAR (p  0.001)
Fig. 3A).
In univariate regression analysis, the occurrence of mod-
rate/severe periAR was associated with an increased risk for
-year mortality (hazard ratio [HR]: 3.9, 95% confidence
nterval [CI]: 2.0 to 7.5; p  0.001 after TAVI (Table 4).
he AR index and outcome. The optimal AR index cutoff
alue for the prediction of mortality at 1 year was calculated
y receiver-operating characteristic curve analysis: Patients
ith AR index 25 had a significantly increased 1-year
ortality risk, compared with patients with AR index 25
46.0% vs. 16.7%: p  0.001) (Fig. 3B). In multivariate
egression analysis, the AR index independently predicted
-year mortality (HR: 2.9, 95% CI: 1.3 to 6.4; p 
.009)—even after adjustment for the severity of periAR.
Because both parameters—severity of periAR and the
emodynamic AR index—impact outcome of TAVI pa-
ients and are readily assessable immediately after valve
After TAVI According to the Degree of PeriARers at 48 h After TAVI According to the Degree of PeriAR
eriAR
71)
Moderate PeriAR
(n  18)
Severe PeriAR
(n  4) p Value
8.3 15.6 7.0 23.3 7.0 0.011
10.3 40.0 8.2 30.0 7.1 0.001
10.5 24.4 9.0 6.8 3.9 0.001
8.5 19.6 7.6 7.6 2.6 0.001
4.7 10.1 6.0 10.2 7.5 0.001
.0/4,244.0) 4,333.0 (1,047.5/9,568.0) 12,197.5 (4,025.0/24,411.0) 0.009
/1.65) 1.06 (0.67/5.22) 3.98 (0.98/5.98) 0.009
Figure 2 AR Index According to Degree of PeriAR
The AR index according to the degree of periAR as assessed by echocardiogra-
phy after transcatheter aortic valve implantation. Abbreviations as in Figure 1.8 hamet
Mild P
(n 
12.0
46.0
34.0
28.0
16.0
0 (470
5 (0.26peptide; TAVI  transcatheter aortic valve implantation; other abbreviations as in Table 1.
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Abbreviations as in Tables 1 and 2.
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Aortic Regurgitation Index Predicts Outcome After TAVI March 27, 2012:1134–41implantation in the catheterization laboratory, we stratified
our study population accordingly (Fig. 4). The 1-year
mortality risk, attributed to the severity of periAR (none/
mild vs. moderate/severe), could be further stratified by the
AR index (p  0.001). In patients with none/mild periAR,
an AR index25 (n 91) was related to a 1-year mortality
ate of 15.4%, whereas an AR index 25 (n  33) was
ssociated with a more-than 2-fold higher 1-year mortality
ate of 33.3%. Patients with moderate/severe periAR and
R index 25 (n  17) had the worst outcome, with a
-year mortality rate of 70.6%.
iscussion
n this prospective study of 146 TAVI patients who
nderwent TAVI with the Medtronic CoreValve prosthesis,
he degree of periAR after TAVI, quantified by echocardi-
graphy, was related to a significant increase in the risk of
hort- and long-term mortality. The AR index, which was
alculated as the ratio of the end-diastolic gradient across
he valve prosthesis to systolic blood pressure, decreased
tepwise in parallel with increasing severity of periAR and
llowed a precise judgment of the degree of periAR. This
emodynamic parameter also strongly predicted 1-year
ortality after TAVI—independent of the degree of
eriAR—and provided additional prognostic information
hat was complementary to the echocardiographically as-
essed severity of periAR.
redictors of periAR after TAVI. Heavily calcified cusps,
isplacement of the prosthesis, and/or annulus-prosthesis-size
ismatch can cause periAR (Fig. 5). We confirmed that
nnulus diameter and prosthesis implantation depth are
ssociated with the occurrence of moderate/severe periAR
fter TAVI (3–6,9). Furthermore, the cover index, which
s a surrogate for prosthesis/annulus incongruence, was
ignificantly lower in patients with moderate/severe periAR
n our study cohort (4). This significant relationship be-
ween low cover index and AR suggests that a certain degree
f prosthesis oversizing is needed to ensure an adequate
daptation of the prosthesis to the aortic annulus. Con-
ersely, recent data indicated that greater oversizing of the
urrence of
ld PeriAR
124)
Moderate/Severe PeriAR
(n  22) p Value
.0) 5 (22.7) 0.001
0.2) 14 (63.6) 0.001
.8) 2 (9.1) 0.42
.4) 1 (4.5) 0.57
9.5) 4 (18.2) 0.82
.1) 1 (4.5) 0.82
0.2) 9 (40.9) 0.034
3.4) 3 (13.6) 0.31Figure 3 Freedom From All-Cause Mortality
Kaplan-Meier estimates of cumulative survival according to the degree of periAR as
assessed by echocardiography (A) and according to the AR index (B). CI  confidence
interval; HR  hazard ratio; other abbreviations as in Figure 1.Clinical Outcomes According to the Occurrence ofModerate/Severe PeriAR After TAVITable 3 Clinical Outcomes According to th OccModerate/Severe PeriAR After TAVI
All Patients
(N  146)
None/Mi
(n 
30-day mortality 10 (6.8) 5 (4
1-yr mortality 39 (26.7) 25 (2
Stroke 8 (5.5) 6 (4
MI 4 (2.7) 3 (2
Minor vascular complications 28 (19.3) 24 (1
Major vascular complications 11 (7.6) 10 (8
AKI 34 (23.3) 25 (2
Pacemaker implantation 32 (21.9) 29 (2alve with respect to the aortic annulus was not associated
Table
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March 27, 2012:1134–41 Aortic Regurgitation Index Predicts Outcome After TAVIwith lesser incidence and severity of periAR, suggesting that
other mechanisms such as the degree of valve calcification or
leaflet-commissural deformation might have additional im-
pact (5). These observations would explain at least in part
why in some of our patients the degree of periAR could not
be improved, despite appropriate implantation depth and
post-dilation maneuvers.
PeriAR and outcome after TAVI. Recent analyses sug-
gested the importance of post-procedural periAR for short-
and long-term outcome (2,6). In our analysis, moderate/
severe periAR, which occurred in 15% of our patients, was
strongly related to both 30-day and 1-year mortality. In
addition, the AR index was a strong and independent predictor
of 1-year mortality risk—even after adjustment for the severity
of periAR—indicating the independent relevance of objec-
tively assessed hemodynamic changes in the long run.
Cox Regression Analysis of the AssociationBetwe n Clinical Characteristics and 1-Year MoTable 4 Cox Regressi n Analy is of the AssBetween Clinical Characteristics an
Univariate HR
(95% CI)
AKI 6.1 (3.2–11.5)
Pulmonary hypertension 3.3 (1.7–6.3)
Moderate/severe periAR 3.9 (2.0–7.5)
AR index 25 3.0 (1.6–5.6)
Coronary artery disease 2.3 (1.1–4.9)
COPD 1.8 (0.9–3.6)
Chronic renal failure 2.0 (1.0–4.1)
Logistic EuroSCORE 1.0 (1.0–1.1)
STS score mortality 1.1 (1.0–1.1)
CI  confidence interval; HR  hazard ratio; other abbreviations as in
Figure 4 1-Year Mortality According to Severity of PeriAR and
1-year all-cause mortality (%) according to the severity of periAR (none/mild vs. moOur data demonstrate that all measures must be taken to
avoid moderate/severe periAR. Thus, effective counter-
measures to decrease periAR might increase survival. Bal-
loon valvuloplasty is usually the first step to optimize
moderate/severe periAR in patients with appropriate im-
plantation depth of the prosthesis. Correction of a deep
implantation depth of the prosthesis can be overcome by the
use of snare catheters, whereas for misplaced or embolized
valves, the implantation of a second prosthesis in “valve-in-
valve” technique is the ultimate bailout option (3).
Quantification of periAR after TAVI. The precise quan-
tification of the degree of periAR remains challenging,
despite the recently suggested VARC criteria (3–8). Most
semi-quantitative Doppler parameters of AR severity are
best applied in central regurgitation jets and, hence, might
not be ideal to quantify the frequently diffuse and eccentric
yion
ear Mortality
p Value
Multivariate HR
(95% CI) p Value
0.001 6.9 (3.4–13.9) 0.001
0.001 3.5 (1.8–6.8) 0.001
0.001 2.4 (1.0–5.4) 0.042
0.001 2.9 (1.3–6.4) 0.009
0.026 2.4 (1.0–5.6) 0.04
0.08 2.4 (1.0–5.6) 0.018
0.047 0.6 (0.3–1.5) 0.29
0.001 1.0 (1.0–1.0) 0.61
0.001 1.0 (1.0–1.1) 0.18
1.
R Index
/severe) and the AR index cutoff value. Abbreviations as in Figures 1 and 2.rtalitocia
d 1-Ythe A
derate
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Aortic Regurgitation Index Predicts Outcome After TAVI March 27, 2012:1134–41periAR with circumferential extent in TAVI patients. De-
spite the use of an integrative approach including several
indirect parameters for determination of AR, the method-
ology remains imprecise (7,8). This is especially applicable
for the acute implantation situation when ideal conditions
for echocardiographic examination are difficult to achieve.
Hemodynamic parameters are easy to quantify and might be
useful for an objective, fast, and reproducible evaluation of
the severity of periAR directly during the procedure—
especially in patients with periAR of borderline significance–
with the possibility to take effective measures to decrease
periAR and thus increase survival.
Study limitations. The AR index varies with the level of the
LVEDP that might be elevated due to high systemic blood
pressure, concomitant diastolic dysfunction, significant myo-
cardial ischemia during balloon valvuloplasty and valve deploy-
ment, or complications related to the TAVI procedure itself
(e.g., tearing of the mitral valve with resultant regurgitation). A
nonspecific elevation of the LVEDP might lead to a low
transvalvular end-diastolic gradient and thus to a false positive
AR index in these cases. This underscores the complementary
value of the AR index, which should be used in addition to
other imaging methods and has its best discriminative ability in
Figure 5 Mechanisms of Peri-Prosthetic Aortic Regurgitation A
Paravalvular leaks with consecutive peri-prosthetic aortic regurgitation result from
of the annulus or the cusps of the native valve (A), valve malposition with too sha
size mismatch (D).patients with borderline periAR.Sample size and the monocentric character are limitations
of our prospective study. Thus, subgroup analyses are only
hypothesis-generating. A larger controlled multicenter trial
might be needed to validate our results.
Conclusions
The assessment of the AR index allows a precise judgment
of periAR, independently predicts 1-year mortality after
TAVI, and provides prognostic information that is comple-
mentary to the degree of periAR. This finding provides a
simple-to-assess, investigator-independent, and immedi-
ately performed parameter, which can be used to guide
peri-procedural clinical decisions in TAVI patients.
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